Overview

A Study to Evaluate IBI112 in the Treatment of Psoriasis With Moderate to Severe Plaque Psoriasis

Status:
Not yet recruiting
Trial end date:
2024-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of participants with moderate to severe plaque-type psoriasis.
Phase:
Phase 3
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.